Annals of Oncology Advance Access published online on March 9, 2007
Annals of Oncology, doi:10.1093/annonc/mdm059
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome
1 Department of Oncology and Pathology, Karolinska Institute and University Hospital, Stockholm, Sweden
2 Laboratory of Cancer Genetics, Institute of Medical Technology and University Hospital of Tampere, Tampere, Finland
3 Department of Pathology, Uppsala University Hospital, Uppsala
4 Stockholm-Gotland Regional Tumor Registry, Oncology Centre, Karolinska University Hospital, Stockholm, Sweden
* Correspondence to: Dr J. Bergqvist, Department of Oncology and Pathology, Radiumhemmet, Karolinska Institute and University Hospital, SE-171 76 Stockholm, Sweden. Tel: +46-8-51776279; Fax: +46-8-51779524; E-mail: jenny.bergqvist{at}ki.se
Background: Our aim was to use quantitative real-time PCR (Q-PCR) and RNA expression profiles (RNA-EPs) to investigate HER2 status in relation to outcome.
Patients and methods: Cut-off levels for Q-PCR and RNA-EP were established in relation to immunohistochemistry (IHC) validated by FISH in a test set of frozen tissue samples from 40 primary breast cancers. The HER2 status was subsequently studied in another validation set of 306 tumors, where Q-PCR and RNA-EP results were compared with previously carried out IHC that we had validated by chromogenic in situ hybridization (CISH).
Results: Q-PCR and RNA-EP offered similar sensitivity (90% versus 77%), specificity (93% versus 95%), and negative (99% versus 98%) and positive (63% versus 61%) predictive values for HER2 determinations. Analyses of relapse-free survival (RFS) and overall survival on the basis of 5 and 10 years of follow-up indicated equivalent hazard ratios for all three techniques. In contrast to IHC/CISH, both Q-PCR and RNA-EP analyses of HER2 also gave statistically significant results regarding RFS and breast cancer-corrected survival after 10 years of follow-up.
Conclusion: The use of RNA-EP and Q-PCR to analyze HER2 in frozen and formalin-fixed breast cancer samples may be an alternate approach to IHC in combination with FISH/CISH.
breast cancer, CISH, diagnostic methods, HER2, quantitative real-time PCR, RNA expression profiles
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine Oncologist, April 1, 2009; 14(4): 320 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Iverson, C. Gillett, P. Cane, C. D. Santini, T. M. Vess, L. Kam-Morgan, A. Wang, M. Eisenberg, C. M. Rowland, J. J. Hessling, et al. A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens J. Mol. Diagn., March 1, 2009; 11(2): 117 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Di Leo The state of HER-2 status Ann. Onc., May 1, 2007; 18(5): 813 - 815. [Full Text] [PDF]
|
|